InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.180 0.08 (3.81%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$813 undetectable PSA level with Cu-67 SAR-bisPSMA 30 Nov 2023 8:54AM $1.300 $2.180 risen by 67.69%
$813 SECuRE theranostic prostate cancer trial progresses 29 Nov 2023 12:55PM $1.300 $2.180 risen by 67.69%
$813 Cleansing Notice 28 Nov 2023 3:27PM $1.270 $2.180 risen by 71.65%
$813 Application for quotation of securities - CU6 28 Nov 2023 3:23PM $1.270 $2.180 risen by 71.65%
$813 Application for quotation of securities - CU6 28 Nov 2023 3:22PM $1.270 $2.180 risen by 71.65%
$813 Results of Meeting 23 Nov 2023 2:12PM $1.300 $2.180 risen by 67.69%
$813 2023 ESG Report 23 Nov 2023 9:25AM $1.310 $2.180 risen by 66.41%
$813 Managing Director's Presentation to AGM 23 Nov 2023 9:15AM $1.310 $2.180 risen by 66.41%
$813 2023 AGM Chair's Address to Shareholders 23 Nov 2023 9:09AM $1.310 $2.180 risen by 66.41%
$813 Bell Potter Healthcare Conference Presentation 15 Nov 2023 8:44AM $1.170 $2.180 risen by 86.32%
$813 Recruitment target achieved for Phase II SAR-Bombesin trial 7 Nov 2023 9:30AM $1.130 $2.180 risen by 92.92%
$813 2023 Appendix 4G 3 Nov 2023 3:28PM $1.125 $2.180 risen by 93.78%
$813 Notification regarding unquoted securities - CU6 1 Nov 2023 1:10PM $1.025 $2.180 risen by 112.68%
$813 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2023 10:33AM $1.055 $2.180 risen by 106.64%
$813 Presentation for Wilsons Drug and Device Conference 27 Oct 2023 9:13AM $1.000 $2.180 risen by 118%
$813 Clarity and PSI kick off SAR-bisPSMA Phase III 26 Oct 2023 9:28AM $1.020 $2.180 risen by 113.73%
$813 Notice of Annual General Meeting/Proxy Form 20 Oct 2023 1:37PM $1.035 $2.180 risen by 110.63%
$813 Notification of cessation of securities - CU6 12 Oct 2023 10:35AM $1.050 $2.180 risen by 107.62%
$813 First patient treated with Cu-67 SAR-Bombesin 3 Oct 2023 9:27AM $1.115 $2.180 risen by 95.52%
$813 Corporate Governance Statement 29 Sep 2023 10:28AM $1.160 $2.180 risen by 87.93%
$813 Annual Report to shareholders 29 Sep 2023 10:07AM $1.160 $2.180 risen by 87.93%
$813 Company Presentation E&P Small Cap Healthcare Conference 13 Sep 2023 9:33AM $1.225 $2.180 risen by 77.96%
$813 BOP preliminary trial results presented at EANM 2023 13 Sep 2023 9:13AM $1.225 $2.180 risen by 77.96%
$813 Revised Change in substantial holding 6 Sep 2023 11:03AM $1.055 $2.180 risen by 106.64%
$813 Change in substantial holding 5 Sep 2023 5:01PM $1.005 $2.180 risen by 116.92%

301 - 325 of 511 results

Page 13 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.